A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 35/4 NEXTHALER (DPI FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE (BDP) 35 µg PLUS FORMOTEROL FUMARATE (FF) 4 µg VERSUS THE FREE COMBINATION OF LICENSED BDP DPI AND FF DPI IN ASTHMATIC CHILDREN

Trial Profile

A SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, 2-WAY CROSS-OVER, CLINICAL PHARMACOLOGY STUDY OF CHF 1535 35/4 NEXTHALER (DPI FIXED COMBINATION OF BECLOMETASONE DIPROPIONATE (BDP) 35 µg PLUS FORMOTEROL FUMARATE (FF) 4 µg VERSUS THE FREE COMBINATION OF LICENSED BDP DPI AND FF DPI IN ASTHMATIC CHILDREN

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Beclometasone/formoterol (Primary) ; Beclometasone; Formoterol
  • Indications Asthma
  • Focus Pharmacokinetics
  • Sponsors Chiesi Farmaceutici
  • Most Recent Events

    • 22 Jun 2017 Status changed from recruiting to completed.
    • 10 Jun 2017 Biomarkers information updated
    • 11 Apr 2017 Planned End Date changed from 1 Mar 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top